This is a working overview of impurity profiling, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-09. Anything still debated is marked as such rather than presented as settled.
Peptide purity testing measures how much of a sample consists of the intended peptide sequence compared with related substances, water, counterions, and residual solvents. No single analytical method captures all of these components at once. Reversed-phase high-performance liquid chromatography with ultraviolet detection is widely used because it separates peptides by hydrophobicity. The reported purity value therefore depends on the chosen method, column, mobile phase, and detection wavelength. Established practice treats purity as method-dependent rather than an absolute property of the material.
Chromatographic separation resolves truncated, oxidized, deamidated, and epimerized peptide variants when their retention times differ from the target. Mass spectrometry confirms molecular mass and can reveal modifications that UV detection misses. Liquid chromatography coupled to mass spectrometry combines separation with identity information, which helps distinguish a pure target from a co-eluting impurity. UV-based area percent can overestimate purity if an impurity lacks a chromophore or if the target and impurity have similar response factors. Researchers often report both chromatographic purity and mass confirmation to give a fuller picture.
Additional techniques address components that reversed-phase chromatography may not resolve. Ion-exchange chromatography separates by charge, size-exclusion chromatography detects aggregates, and capillary electrophoresis offers high separation efficiency. Water content is measured by Karl Fischer titration, residual solvents by gas chromatography, and elemental impurities by inductively coupled plasma mass spectrometry. Amino acid analysis or nitrogen determination can estimate peptide content on a mass basis. Purity is frequently reported as area percent, yet standardized comparison across laboratories remains an open question because methods and reporting practices differ.
Reverse-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. It separates components by hydrophobicity on a column with a water-organic mobile phase. Ultraviolet absorbance at 214 nm or 220 nm detects peptide bonds. The main peak area as a percentage of total peak area gives a purity figure. This figure depends on column, gradient, wavelength, and how peaks are integrated, so it is method-specific rather than absolute.
Mass spectrometry provides complementary information by measuring molecular mass. Electrospray ionization or matrix-assisted laser desorption/ionization can confirm the expected peptide mass and reveal related impurities with different masses. It does not directly quantify all species because ionization efficiency varies. When coupled to liquid chromatography, LC-MS can assign masses to chromatographic peaks. This helps distinguish target peptide from truncation, oxidation, or deletion products. Mass accuracy and resolution determine how confidently a mass can be matched to a proposed structure.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized peptides commonly appear as powders; color can vary with sequence. |
| Solubility class | Variable; often soluble in water or aqueous buffer | Depends on sequence, charge, and hydrophobicity. |
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light; avoid repeated freeze-thaw cycles. |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity confirmation. |
| Common synonyms | Peptide purity analysis; peptide purity assay | Used in certificate of analysis and quality control contexts. |
Storage and handling conditions affect both peptide stability and the accuracy of later purity tests. Lyophilized powders are commonly kept desiccated at -20 °C or below, while reconstituted solutions require a defined buffer, pH, and temperature range. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis over time. Each cycle may alter the chromatogram and complicate comparison with earlier results. Stability data, when available, should guide handling intervals and solvent choice.
Independent verification is used when a supplier result needs confirmation or when a material supports regulated work. A second laboratory can repeat reverse-phase HPLC and mass spectrometry on the same sample. Discrepancies may arise from different columns, gradients, detection wavelengths, or sample preparation. Moisture uptake and counterion content can lower net peptide mass without changing area percent. Documentation of methods and raw data helps distinguish analytical variation from a true quality difference.
Quality control for peptides involves setting specifications for identity, purity, and counterion content. Batches are tested against these specifications before release. Purity specifications often require a minimum area percentage by high-performance liquid chromatography, such as 95% or 98%, depending on the intended application. Additional tests may include water content, acetate or trifluoroacetate content, and residual solvents. These parameters affect the net peptide content and the accuracy of subsequent laboratory experiments.
Stability testing examines how peptide purity changes over time under defined conditions. Accelerated studies use elevated temperatures and humidity to predict degradation pathways, while long-term studies store samples at recommended temperatures. Common degradation reactions include oxidation of methionine, deamidation of asparagine, and hydrolysis of peptide bonds. The results inform expiration dates and storage recommendations for research materials. Lyophilized peptides are generally more stable than solutions, but both forms can degrade if exposed to moisture, oxygen, or repeated freeze-thaw cycles.
Impurity profiling identifies and quantifies substances that coexist with the target peptide. These include deletion sequences, truncated peptides, oxidized variants, and residual protecting groups from synthesis. Reversed-phase chromatography can separate many of these impurities, but co-elution remains a challenge for closely related species. Mass spectrometry helps assign identities to impurity peaks, and impurity limits are often set as area percentages relative to the main peak. Regulatory guidelines for research-grade peptides are less strict than those for therapeutic products, so specifications vary by supplier.
Reversed-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. Separation depends on interactions between peptide residues and a hydrophobic stationary phase, with gradients of water and organic solvent. Ultraviolet detection near 214 nm responds to the peptide backbone and to many related impurities. The resulting chromatogram is often expressed as area percent, which reports the proportion of peak area assigned to the main component. Different columns, gradients, and wavelengths can produce different purity values for the same material.
Mass spectrometry provides complementary information about molecular identity and certain impurities. Electrospray ionization and matrix-assisted laser desorption/ionization are common ionization techniques for peptides. A measured mass close to the expected value supports correct sequence length and modifications, while extra mass signals can reveal truncations, adducts, or incomplete deprotection. Mass spectrometry alone is not a quantitative purity assay, because ionization efficiency varies between compounds. Coupling liquid chromatography to mass spectrometry links retention time with mass and helps assign peaks that ultraviolet detection records.
Orthogonal separation methods address impurities that RP-HPLC may not resolve. Size-exclusion chromatography detects aggregates and higher-order species, while ion-exchange chromatography separates charge variants. Capillary electrophoresis can assess charge-to-mass ratios and, in some formats, size-based impurities. Amino acid analysis and nitrogen determination estimate peptide content rather than chromatographic purity. Because each technique has a different selectivity, a complete purity profile usually combines results from more than one method. The choice of method depends on the impurity classes of concern.
=== Logo === The design was created by McLean Design, a California-based strategic branding firm. The logo is composed of a vibrant green "M", composed of three lines on a field of black. The "M" is stylized in such a way as to imply that it is formed by the claws of a monster ripping through the can.
== Past activity == With the help of then German Chancellor Gerhard Schröder, BASF's Jürgen Hambrecht signed the Gazprom Nord Stream-Yuzhno-Russkoye deal in 2004 with a 49-51 structure, as opposed to the older 50-50 split of for example BP's TNK-BP project. Putin at the time insisted on majority Russian ownership of any joint-venture in Russian territory since that time. BASF expanded to Podolsk, Russia, in 2012, and to Kazan in 2013.
C6H5C(O)CH(NOSO2H) + 2 H2O → C6H5C(O)CHO + NH4HSO4 It may also be prepared from methyl benzoate by a reaction with potassium dimsyl to give an intermediate β-ketosulfoxide, which undergoes a Pummerer-type rearrangement, followed by oxidation by with copper(II) acetate. Alternatively, it can also be prepared by oxidation of acetophenone with selenium dioxide.
Sources: en.wikipedia.org
=== Obstetrics === Fentanyl is sometimes given intrathecally as part of spinal anesthesia or epidurally for epidural anesthesia and analgesia. Because of fentanyl's high lipid solubility, its effects are more localized than morphine, and some clinicians prefer to use morphine to get a wider spread of analgesia. It is widely used in obstetrical anesthesia because of its short time to action peak (about 5 minutes), the rapid termination of its effect after a single dose, and the occurrence of relative cardiovascular stability. In obstetrics, the dose must be closely regulated to prevent large amounts of transfer from mother to fetus. At high doses, the drug may act on the fetus to cause neonatal withdrawal. For this reason, shorter-acting agents such as alfentanil or remifentanil may be more suitable in the context of inducing general anesthesia.
Male - 50.7% Female - 49.3% Native American/Alaskan - 0.1% Asian/Pacific islander - 0.9% Black - 0.3% Hispanic - 96.1% White - 2.4% Multiracial - 0.2% Additionally, 86.3% of the students were eligible for free or reduced lunch.
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is primarily used to treat major depressive disorder and, perhaps more especially, obsessive–compulsive disorder (OCD), but is also used to treat anxiety disorders such as panic disorder, social anxiety disorder, and post-traumatic stress disorder. Fluvoxamine's side-effect profile is similar to that of other SSRIs. Common adverse effects include constipation, gastrointestinal problems, headache, anxiety, irritation, sexual problems, dry mouth, sleep problems, and an increased risk of suicide at the start of treatment. These effects appear to be significantly weaker than with other SSRIs, with the exception of gastrointestinal side-effects. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that fluvoxamine's product labeling warn of this risk. Fluvoxamine appears to be more tolerable than other SSRIs, particularly with respect to cardiovascular complications. It is on the World Health Organization's List of Essential Medicines.
Edwin Haslam (1993). Shikimic Acid: Metabolism and Metabolites (1st ed.). ISBN 0471939994. Brown, Stewart A.; Neish, A. C. (1955). "Shikimic Acid as a Precursor in Lignin Biosynthesis". Nature. 175 (4459): 688–689. Bibcode:1955Natur.175..688B. doi:10.1038/175688a0. ISSN 0028-0836. PMID 14370198. S2CID 4273320. Weinstein, L. H.; Porter, C. A.; Laurencot, H. J. (1962). "Role of the Shikimic Acid Pathway in the Formation of Tryptophan in Higher Plants : Evidence for an Alternative Pathway in the Bean". Nature. 194 (4824): 205–206. Bibcode:1962Natur.194..205W. doi:10.1038/194205a0. ISSN 0028-0836. S2CID 4160308. Wilson, D J; Patton, S; Florova, G; Hale, V; Reynolds, K A (1998). "The shikimic acid pathway and polyketide biosynthesis". Journal of Industrial Microbiology and Biotechnology. 20 (5): 299–303. doi:10.1038/sj.jim.2900527. ISSN 1367-5435. S2CID 41117722.
Sources: en.wikipedia.org
It usually refers to the relative peak area of the target peptide in a chromatogram, not the mass fraction of the entire sample. Different analytical methods can yield different purity values. Water, counterions, and residual solvents are excluded unless the calculation specifies otherwise.
A single method can miss co-eluting impurities, salts, water, or structural modifications. Orthogonal techniques separate compounds by different properties, such as hydrophobicity, charge, or size. Combining results gives a more complete assessment of sample composition.
No, purity measures the amount of target relative to other peaks, not the identity or sequence of the target. Mass spectrometry and sequencing may be needed to confirm structure. A high-purity sample can still contain a peptide with an incorrect sequence.
It usually refers to the relative area of the main peak in a chromatographic separation, such as RP-HPLC. It estimates the proportion of UV-absorbing material in that peak, not the absolute mass fraction of the target peptide. Different methods can give different percentages.